^
Association details:
| Biomarker: | TROP2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | datopotamab deruxtecan (DS-1062a) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
33P - Antitumor activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models
Published date:
05/07/2023
Excerpt:
We assessed the antitumor activity in a panel of breast cancer PDXs varying in TROP2 expression….In isogenic breast cancer cell lines, overexpression of TROP2 expression conferred in vitro antitumor activity of Dato-DXd
